To evaluate the feasibility, local control, and survival after computed tomography (CT)-guided cryoablation for adrenal metastases. This study included 31 consecutive patients with adrenal metastases who were treated by CT-guided cryoablation in our center from July 2011 to October 2017. The technical success rate, local progression rate, local progression-free survival (LPFS), systemic progression-free survival (SPFS). and overall survival were assessed. The predictors of survival were determined using univariate and multivariate Cox regression analyses. The primary and secondary technical success rates were 90.3% and 100%. respectively. None of the patients experienced a hypertensive crisis. The local progression rate during follow-up was 19.4%. Systemic progression was found in 9 patients. The cumulative 1-, 3-, and 5-year LPFS rates were 80.6%, 37.8%, and 18.4%, respectively. The cumulative 1-, 3-, and 5-year SPFS rates were 77.4%, 31.9%, and 14.6%, respectively. The cumulative 1-, 3-, and 5-year overall survival rates were 83.9%, 45.0%, and 30.0%, respectively. The existence of an extra-adrenal tumor was a significant independent predictor of worse overall survival (P=.012). The mean overall survival durations were significantly different between patients with and without an extra -adrenal tumor (16.6 +/- 24 vs 50.9 +/- 4.5 months, P<.001). Our findings support that CT-guided cryoablation is a safe and effective method for controlling adrenal metastases and imply that this approach may improve the survival of patients with adrenal metastases.